Match Day at the David Geffen School of Medicine
Extending medical education to a broader segment of tomorrow's physicians and researchers, the UCLA School of Medicine has established two innovative programs - the UC Riverside/UCLA Biomedical Sciences Program and the Drew/UCLA Medical Education Program
UC Riverside/UCLA Thomas Haider Program in Biomedical Sciences The UCR/UCLA Thomas Haider Program in Biomedical Sciences at the University of California, Riverside will graduate its final class in 2016. These students completed the first two years of medical school at UC Riverside and are currently completing the clinical training program at UCLA. UC, Riverside, School of Medicine, admitted its first class in the fall of 2013.
UCLA PRIME The UCLA PRIME program is a 5-year dual degree program focusing on the development of leaders in medicine who will improve health care delivery, research, and policy in underserved communities. Masters degrees may be completed in areas that complement the mission of the program, generally an MBA, MPH or MPP. The annual cohort is composed of 18 students. Students will identify with one of two programs: PRIME UCLA-Westwood (14) or PRIME UCLA-CDU (4). A commitment to serve in, and experience working with, diverse medically disadvantaged populations is paramount. While the program is fully coordinated with the other medical student programs, application and acceptance are specific to UCLA PRIME.
Drew/UCLA Medical Education Program The Drew/UCLA program was established in 1978 between the Charles R. Drew University of Medicine and Science in south central Los Angeles and the UCLA School of Medicine. Its mission is to train students to practice medicine with competence and compassion in disadvantaged rural and urban communities. Medical students in the program take their first two years of basic medical science coursework at UCLA, then complete their last two years of clinical work at the King/Drew Medical Center on the Drew campus. Twenty-four students per year are admitted to the program.